Status:
UNKNOWN
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The clinical trial was designed to prove that Arsenic plus ATRA possibly had an effect on improving the symptoms, reducing the early mortality rate and prolonging the total survival time of patients w...
Detailed Description
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a highly variable prognosis and an overall high mortality rate. The 5-year overall survival of adult AML patients is less than ...
Eligibility Criteria
Inclusion
- Newly diagnosed or relapsed AML.Diagnosis based on Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia(not APL)(2018)
- Older than 18 years old
- Patients or their families signed written informed consent
Exclusion
- Be allergic to the drug ingredient, the supplementary material or the allergic constitution person
- Cardiac insufficiency, renal insufficiency, significant arrhythmias, EKG abnormalities or other important organ dysfunction
- Combined with other malignant tumors
- Pregnant and lactating women
- Participants in other drug trials in the last 3 months
- Suffering from mental illness or other circumstances which unable to carry out the plan
- Other patients who were not suitable for the study
Key Trial Info
Start Date :
February 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05297123
Start Date
February 3 2019
End Date
December 31 2023
Last Update
March 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710016